The Bergand Group offers a high-focus method for the treatment of behavioral health and addictive conditions in adolescents.

BEL AIR, Md (PRWEB) May 05, 2016

The Bergand Group offers a high-focus method for the treatment of behavioral health and addictive conditions in adolescents. This individualized approach joins the family and community in the treatment process. The Bergand Group’s Adolescent Treatment Program offers after-school programs as well as coordination with parents.

With over 25 years of experience, The Bergand Group’s doctors and clinicians now offer treatment to teens, adolescents, and families. Each of their clients receive treatment and attention from a multidisciplinary team of professionals.

The Bergand Group was founded by Dr. John Steinberg and Dr. Paul Giannandrea, two experienced and complimentary doctors who joined together to create a true Dual Diagnosis and Co-Occurring Disorder treatment program. The Bergand Group provides a setting in which patients can be treated, and in which clinicians can work, in a therapeutic and comfortable environment that embodies their core principles.

ABOUT THE DOCTORS:

Dr. John Steinberg is a co-founder and the Medical Director of The Bergand Group. He is certified in Addiction Medicine and served as President of the Maryland Society of Addiction Medicine from 1990 through 2005. Dr. Steinberg was the first head of the division of Addiction Medicine at GBMC and has treated addiction for over 25 years.

Dr. Paul Giannandrea is a co-founder and the Clinical Director of The Bergand Group. He is a Psychiatrist certified in Addiction Medicine and previously served as the director of the University of Maryland Medical Center’s Outpatient Clinic and the medical director of Pathways Treatment Center in Annapolis. Dr. Giannandrea has also treated addiction for over 25 years.

For more information, visit http://www.bergandgroup.com/adolescent-treatment.

advertisement | advertise on newsday

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/05/prweb13389532.htm